Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2023-04-07 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
2022年度独立董事述职报告（汪思佳）
Board/Management Information Classification · 95% confidence The document is a detailed annual performance report of an independent director (汪思佳) of the company 成都市贝瑞和康基因技术股份有限公司 for the year 2022. It includes attendance records at board and shareholder meetings, independent opinions on various board resolutions, supervision activities, and other governance-related duties. The content focuses on the director's role, governance oversight, and compliance with legal and regulatory requirements. It does not contain financial statements or audit results, nor is it a transcript, announcement, or presentation. This fits the category of Board/Management Information (MANG), which covers announcements or reports related to changes or activities of the board or senior management, including independent directors' reports.
2023-04-07 Chinese
2022年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled '2022 年度董事会工作报告' which translates to '2022 Annual Board of Directors Work Report' for Chengdu Berry Genomics Co., Ltd. It contains detailed information about the company's business development, financial status, board meetings, governance, and future plans for the year 2022. The content includes comprehensive discussion of the board's activities, strategic decisions, committee reports, and governance practices. It is not a full annual report with financial statements but rather a detailed report on the board's work and governance for the year. This fits the category of Board/Management Information (MANG), which covers announcements and reports about changes and activities of the board and senior management. The document length (9736 characters) and detailed content support this classification rather than a brief announcement or a full annual report (10-K).
2023-04-07 Chinese
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 25th meeting of the 9th Board of Directors of the company. It includes approvals of the 2022 Annual Report, 2022 Financial Statements, Board and General Manager Work Reports, Internal Control Self-Evaluation Report, and other related matters. The document repeatedly states that these reports will be submitted to the 2022 Annual General Meeting for approval and that the full reports are published separately on a public information website. The document itself does not contain the full financial reports or detailed financial data but rather announces the board's resolutions and references the availability of the full reports elsewhere. The document length is about 3011 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of board meeting resolutions and report approvals, not the reports themselves.
2023-04-07 Chinese
2022年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2022年度监事会工作报告" which translates to "2022 Supervisory Board Work Report". It details the supervisory board's activities, oversight of financial management, internal controls, compliance with laws and regulations, and governance matters for the year 2022. It includes review and opinions on financial reports, internal controls, related party transactions, and insider information management. The document is a comprehensive report from the supervisory board on their work and oversight for the fiscal year 2022. It is not an annual report (10-K), audit report (AR), or interim report (IR), but rather a management-related report focusing on supervisory board activities and governance oversight. This fits best under Management Reports (MDA), which cover management's detailed explanation of financial results, business trends, and outlook, including supervisory board reports. The document length is 2617 characters, which is consistent with a detailed report but not a brief announcement or certification. Therefore, the classification is MDA with high confidence.
2023-04-07 Chinese
2022年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for 成都市贝瑞和康基因技术股份有限公司, issued by a registered accounting firm. It contains detailed audit opinions, basis for audit opinions, key audit matters such as revenue recognition and accounts receivable impairment, responsibilities of management and auditors, and extensive notes on accounting policies and financial statement preparation. The document includes detailed financial statement notes and explanations consistent with an audit report rather than a full annual report or other filing types. The length is substantial (15,000 characters), indicating it is the full audit report, not just an announcement or certification. Therefore, the document fits the category of Audit Report / Information (AR). FY 2022
2023-04-07 Chinese
关于 2022 年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by the company regarding the 2022 annual asset impairment provision. It details the amount of impairment, the accounting basis, and the impact on financial results. It includes statements from the board, independent directors, and the supervisory board approving the impairment provision. The document is relatively short (1676 characters) and serves as a formal disclosure of a specific accounting action rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a certification or a regulatory compliance filing. The content fits best with a Regulatory Filing (RNS) as it is a formal announcement of an accounting provision and related approvals without being a full report or presentation.
2023-04-07 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.